Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 4/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679730 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL30679729 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL265264 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29527284 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29420016 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29382390 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29528046 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29540545 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29528171 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29867949 | 0.94 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190270787-A1 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF | BOLDER BIOTECHNOLOGY, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10329337-B2 | Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11 | BOLDER BIOTECHNOLOGY, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170369547-A1 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF | BOLDER BIOTECHNOLOGY, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9637530-B2 | Methods of preparing cysteine variants of human recombinant IL-11 | BOLDER BIOTECHNOLOGY, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160200790-A1 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF | BOLDER BIOTECHNOLOGY, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-7399839-B2 | Monopegylated growth hormone proteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070111240-A1 | Cysteine variants of interleukin-11 and methods of use thereof | BOLDER BIOTECHNOLOGY, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20050187160-A1 | Monopegylated growth hormone proteins | BOLDER BIOTECHNOLOGY INC. (US) | 2005-08-25 | — | — | US | disclosed |
| CN-1210400-C | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050026834-A1 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1200124-A4 | IMMUNOGLOBULIN FUSION PROTEINS | BOLDER BIOTECHNOLOGY INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6753165-B1 | FOR RESIDUES THAT DO NOT FORM DISULFIDE BOND | BOLDER BIOTECHNOLOGY, INC. | 2004-06-22 | — | — | US | disclosed |
| CN-1355842-A | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC (US) | 2002-06-26 | — | — | CN | disclosed |
| EP-1200124-A1 | IMMUNOGLOBULIN FUSION PROTEINS | Bolder Biotechnology, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001003737-A1 | IMMUNOGLOBULIN FUSION PROTEINS | BOLDER BIOTECHNOLOGY INC. (US) | 2001-01-18 | — | — | WO | disclosed |